In fall 2005, cancer investigators from a variety of disciplines, including members of the five CCSG programs and of the Multidisciplinary Groups, submitted 28 proposals involving more than 60 researchers from throughout the University of Utah. Six proposals received funding under this program.

Cyclooxygenase-2 expression as a therapeutic target in meningiomas
Principal Investigator: William Couldwell, MD, PhD
Department: Neurosurgery
Collaborators: John Hoffman, MD; Randy Jensen, MD, PhD; Stephen Prescott, MD

Clinical and molecular pharmacology of Zileuton (ZyFLO) in pancreatic cancer
Principal Investigator: Frank Fitzpatrick, PhD
Department: Oncological Sciences
Collaborators: Wallace Akerley, MD; Matt Firpo, PhD; Sean Mulvihill, MD; Courtney Scaife, MD

NF-B inhibitors are a novel class of drugs that may prevent cancer seeding and metastasis in humans
Principal Investigator: Scott Kuwada, MD
Department: Internal Medicine, Gastroenterology
Collaborators: Glenn Prestwich, PhD; Courtney Scaife, MD

The role of Notch signaling in pancreatic cancer
Principal Investigator: L. Charles Murtaugh, PhD
Department: Human Genetics

Epigenetic potentiation of Interferon-a using the DNA methylation inhibitor Decitabine: A Phase I study with molecular correlates
Principal Investigator: Wolfram Samlowski, MD
Department: Internal Medicine, Oncology
Collaborators: Wallace Akerley, MD; Ken Boucher, PhD; Frank Fitzpatrick, PhD; Gina Gregovich; Sancy Leachman, MD, PhD; Mark Wade, PhD; Margaret Yu, MD

Identifying small molecule drugs for the treatment of immune-mediated diseases using transgenic zebrafish
Principal Investigator: Nikolaus Trede, MD, PhD
Department: Pediatrics
Collaborators: Frank Fitzpatrick, PhD; Gerald Spangrude, PhD